Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer [clinicaltrials:NCT00079872]

Bio2RDF identifier

NCT00079872

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00079872

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00079872

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

In this study, patients ...... ients with colorectal cancer.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Pemetrexed Plus a Comparator V ...... Treatment of Colorectal Cancer

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:f4e2d14aca79345b8549405aad2d71b6]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:0ada54df040c6bb7ec7c478a0cfca9b1]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:1914680358a341dc988921ed0c680bc4]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:410fc75849207613d8c6cbd191480e64]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:556cd17ea2dc44f5830cdc8fcd6970db]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:6c402c5c72bf7f6448fbc5ca5ea57c86]

The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:eab329087610188b370c1cb404f7a911]

completion date [clinicaltrials_vocabulary:completion-date]

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00079872 [clinicaltrials_resource:d44b2fcf7e9fef4173e54d10f43f2b89]

enrollment [clinicaltrials_vocabulary:enrollment]

120

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2004-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Pemetrexed [clinicaltrials_resource:df327e7bec62528cede68fc4b0399f01]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Pemetrexed [clinicaltrials_resource:24372f04057ac170feba0367044871bd]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2007-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

link [clinicaltrials_vocabulary:link]

Lilly Clinical Trial Registry [clinicaltrials_resource:83adce4c7f71cdc37c40acbca0949b69]

location [clinicaltrials_vocabulary:location]

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician [clinicaltrials_resource:65c126759c911f271f26189297531aae]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00079872

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Randomized Phase 2 Trial of ...... r Metastatic Colorectal Cancer

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2,929

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:3b2c072f348385b5511b7c6ef47389ea]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

secondary id [clinicaltrials_vocabulary:secondary-id]

H3E-MC-JMAZ

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

start date [clinicaltrials_vocabulary:start-date]

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00079872 study design [clinicaltrials_resource:f8480439bae58aac3c7329a83c41d2ae]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00079872

verification date [clinicaltrials_vocabulary:verification-date]

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00079872

http://www.w3.org/2001/XMLSchema#string

title

Pemetrexed Plus a Comparator V ...... Treatment of Colorectal Cancer

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Pemetrexed Plus a Comparator V ...... r [clinicaltrials:NCT00079872]

@en